• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.抗环瓜氨酸肽抗体阴性的类风湿关节炎是否由与持续无改善病情抗风湿药缓解及疾病初发时的血清学标志物相关的亚组构成？对Boeters DM等人文章的评论
Arthritis Res Ther. 2020 Jan 31;22(1):17. doi: 10.1186/s13075-020-2106-5.
2
ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.ACPA 阴性 RA 包括多个亚组：在疾病发病时通过血清学标志物可以识别出有可能实现持续无 DMARD 缓解的患者。
Arthritis Res Ther. 2019 May 14;21(1):121. doi: 10.1186/s13075-019-1902-2.
3
Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.解析 ACPA 阴性类风湿关节炎的异质性：在开始 DMARD 治疗时具有强烈临床和血清学反应的患者亚组有利于疾病缓解。
Arthritis Res Ther. 2022 Jan 3;24(1):4. doi: 10.1186/s13075-021-02671-z.
4
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.类风湿关节炎患者的经济有效的降阶梯算法：多生物标志物疾病活动评分与自身抗体状态的结合。
J Rheumatol. 2019 May;46(5):460-466. doi: 10.3899/jrheum.180028. Epub 2018 Dec 1.
5
Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.当前的治疗策略能否实现免疫缓解，即自身抗体的消失？一项对达到持续无 DMARD 状态的类风湿关节炎患者进行的长期随访研究。
Ann Rheum Dis. 2019 Nov;78(11):1497-1504. doi: 10.1136/annrheumdis-2018-214868. Epub 2019 Aug 14.
6
Response to: "Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation" by Masi and Fleischmann.对Masi和Fleischmann所著《ACPA阴性类风湿关节炎是否由与疾病初发时持续无DMARD缓解及血清学标志物相关的亚组构成》一文的回应
Arthritis Res Ther. 2020 Mar 20;22(1):55. doi: 10.1186/s13075-020-02152-9.
7
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.在逐渐减少改善病情抗风湿药（DMARD）治疗的类风湿关节炎患者中，通过多种生物标志物疾病活动度和自身抗体状态预测疾病复发
Ann Rheum Dis. 2016 Sep;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900. Epub 2015 Oct 19.
8
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.抗瓜氨酸化蛋白抗体反应在接受达标治疗的类风湿关节炎起始队列患者中的作用。
Arthritis Res Ther. 2018 Jul 13;20(1):146. doi: 10.1186/s13075-018-1635-7.
9
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.在德国、意大利、西班牙、美国和加拿大，按抗环瓜氨酸肽（ACPA）亚组划分，类风湿关节炎中阿巴西普与阿达木单抗的每反应成本。
Rheumatol Int. 2017 Jul;37(7):1111-1123. doi: 10.1007/s00296-017-3739-9. Epub 2017 May 30.
10
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.与第二代抗环瓜氨酸肽和类风湿因子相比，抗瓜氨酸化波形蛋白和第三代抗环瓜氨酸肽在预测未分化关节炎和类风湿关节炎疾病转归中的价值。
Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

引用本文的文献

1
Response to: "Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation" by Masi and Fleischmann.对Masi和Fleischmann所著《ACPA阴性类风湿关节炎是否由与疾病初发时持续无DMARD缓解及血清学标志物相关的亚组构成》一文的回应
Arthritis Res Ther. 2020 Mar 20;22(1):55. doi: 10.1186/s13075-020-02152-9.

本文引用的文献

1
ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.ACPA 阴性 RA 包括多个亚组：在疾病发病时通过血清学标志物可以识别出有可能实现持续无 DMARD 缓解的患者。
Arthritis Res Ther. 2019 May 14;21(1):121. doi: 10.1186/s13075-019-1902-2.
2
Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?多生物标志物疾病活动评分预测类风湿关节炎缓解的价值：证据表明了什么？
J Rheumatol. 2019 May;46(5):443-446. doi: 10.3899/jrheum.181061.
3
Complex Relationships of Smoking, HLA-DRB1 Genes, and Serologic Profiles in Patients With Early Rheumatoid Arthritis: Update From a Swedish Population-Based Case-Control Study.早期类风湿关节炎患者吸烟、HLA-DRB1 基因与血清学特征的复杂关系：来自瑞典基于人群的病例对照研究的更新。
Arthritis Rheumatol. 2019 Sep;71(9):1504-1511. doi: 10.1002/art.40852. Epub 2019 Jul 24.

Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation? Comment on article by Boeters DM et al.

作者信息

Masi Alfonse T, Fleischmann Roy

机构信息

Department of Medicine, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL, USA.

Co-Medical Director Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, 8144 Walnut Hill Lane Suite 810, Dallas, TX, 75231, USA.

出版信息

Arthritis Res Ther. 2020 Jan 31;22(1):17. doi: 10.1186/s13075-020-2106-5.

DOI:10.1186/s13075-020-2106-5
PMID:32005276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6993512/
Abstract
摘要